Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903353 · ClinicalTrials.gov registry record · Phase 4
Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT04903353 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT04903353, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.
Interventions
- DRUG Comparison of Risperidone and Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903353
The ClinicalTrials.gov registry entry for NCT04903353 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Comparison of Risperidone and Aripiprazole is the first listed.
NCT04903353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04903353 about?
NCT04903353 is a clinical study titled "Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole". This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is asso...
What is the current status of trial NCT04903353?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2022-02-01. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT04903353?
The interventions under investigation include: Comparison of Risperidone and Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT04903353?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.